Moleculin Announces Successful Expansion of its Leukemia Drug Program

Moleculin Biotech announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. in Latina, Italy.

"Securing production supply for a liposomal anthracycline like Annamycin is no trivial matter, which is why we partnered last year with a quality supplier like BSP, who will be able to supply Annamycin in commercial quantities going forward," said Walter Klemp, Moleculin's Chairman and CEO. "They have worked diligently to establish production capability and are now supplying our Annamycin drug for our clinical trials in the U.S. and the EU. We believe having a partnership with a pharmaceutical manufacturer the caliber of BSP mitigates our development risk and better positions us to further advance the clinical development of Annamycin as we work to develop effective solutions for the treatment of acute myeloid leukemia."

  • <<
  • >>